NO20002967L - Uretans derived from azacycloalkanes, thio and dithio analogues, as well as the use and preparation of 2,3 eposkysqualene-lanesterol cyclase inhibitor - Google Patents

Uretans derived from azacycloalkanes, thio and dithio analogues, as well as the use and preparation of 2,3 eposkysqualene-lanesterol cyclase inhibitor

Info

Publication number
NO20002967L
NO20002967L NO20002967A NO20002967A NO20002967L NO 20002967 L NO20002967 L NO 20002967L NO 20002967 A NO20002967 A NO 20002967A NO 20002967 A NO20002967 A NO 20002967A NO 20002967 L NO20002967 L NO 20002967L
Authority
NO
Norway
Prior art keywords
group
atom
represent
alkyl
oxygen
Prior art date
Application number
NO20002967A
Other languages
Norwegian (no)
Other versions
NO20002967D0 (en
Inventor
Roland Maier
Peter Mueller
Gebhard Schilcher
Gebhard Adelgoss
Rudolf Hurnaus
Michael Mark
Bernhard Eisele
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of NO20002967D0 publication Critical patent/NO20002967D0/en
Publication of NO20002967L publication Critical patent/NO20002967L/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23KFODDER
    • A23K20/00Accessory food factors for animal feeding-stuffs
    • A23K20/10Organic substances
    • A23K20/116Heterocyclic compounds
    • A23K20/132Heterocyclic compounds containing only one nitrogen as hetero atom
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23KFODDER
    • A23K50/00Feeding-stuffs specially adapted for particular animals
    • A23K50/70Feeding-stuffs specially adapted for particular animals for birds
    • A23K50/75Feeding-stuffs specially adapted for particular animals for birds for poultry
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • C07D211/44Oxygen atoms attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/54Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C07D211/64Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4 having an aryl radical as the second substituent in position 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Birds (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Animal Husbandry (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Fodder In General (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

Det er beskrevet uretaner avledet fra axacykloalkaner i tillegg til tio og ditio- analoger ifølge generell formel (I), hvori m er lik O eller 1, n er lik 1 eller 2, A er en enkeltbinding, en lineær eller forgrenet C^alkylengruppe, en C2-aalkenylen eller C2. aalkylengruppe, idet en umettet gruppe ikke er direkte bundet til resten Y; X og Y er et oksygen eller svovelatom, R1 og R2 er en lineær eller forgrent d-ealkylgruppe, en C^alkengruppe eller Ci^alkenylgruppe, hvorved en multippel binding er isolert fra nitrogen-karbonbindingen, eller R1 og R2 sammen med nitrogenatomet representerer en 5-7 leddet mettet heterocyklisk ring, hvorved en metylengruppe isolert fra nitrogen- atomet kan bli erstattet av et oksygen eller svovelatom eller av en -NH eller -N (alkyl)- gruppe, R3-R6 kan være identiske eller forskjellige og representerer hydrogenatomer eller alkylgrupper, R7 er en C^cykloalkylgruppe, eventuelt en fenyl eller naftylgruppe substituert med to halogenatomer, en alkyl, alkoksy, trifluormetyl eller cyanogruppe eller et hydrogenatomer, forutsatt at A ikke representerer en enkeltbinding, E er et oksygen eller sovelatom, en metylen, karbonyl eller sulfinylgruppe og R8 representerer et hydrogenatom eller E representerer -C(R9R10)-gruppen, hvori R10 og ved sidenav liggende gruppe R8 representerer en karbon-karbon-binding. Det er også beskrevet entaniomerer, diastereomerer og salter derav, spesielt fysiologisk akseptable syre- additive salter med verdifulle egenskaper som utviser en inhiberende effekt på kolesterolbiosyntesen, i tillegg til medikamenter inneholdende nevnte forbindelse, anvendelse derav og en fremgangsmåte for fremstilling derav.There are disclosed urethanes derived from axacycloalkanes in addition to ten and dithio analogues of general formula (I), wherein m is 0 or 1, n is 1 or 2, A is a single bond, a linear or branched C 1-6 alkylene group, a C2 alkenylene or C2. alkylene group, an unsaturated group not directly bonded to the residue Y; X and Y are an oxygen or sulfur atom, R 1 and R 2 are a linear or branched d -alkyl group, a C 1-6 alkenyl or C 1-6 alkenyl group, whereby a multiple bond is isolated from the nitrogen-carbon bond, or R 1 and R 2 together with the nitrogen atom represent a 5-7 membered saturated heterocyclic ring, wherein a methylene group isolated from the nitrogen atom may be replaced by an oxygen or sulfur atom or by an -NH or -N (alkyl) group, R3-R6 may be identical or different and represent hydrogen atoms or alkyl groups, R 7 is a C 1-4 cycloalkyl group, optionally a phenyl or naphthyl group substituted with two halogen atoms, an alkyl, alkoxy, trifluoromethyl or cyano group or a hydrogen atom, provided that A does not represent a single bond, E is an oxygen or sleeping atom, a methylene, carbonyl or sulfinyl group and R 8 represents a hydrogen atom or E represents the -C (R 9 R 10) group wherein R 10 and adjacent R 8 represent a carbon-carbon bi nding. Also included are entaniomers, diastereomers and salts thereof, especially physiologically acceptable acid-additive salts having valuable properties which exhibit an inhibitory effect on cholesterol biosynthesis, in addition to medicaments containing said compound, its use and a process for its preparation.

NO20002967A 1997-12-10 2000-06-09 Uretans derived from azacycloalkanes, thio and dithio analogues, as well as the use and preparation of 2,3 eposkysqualene-lanesterol cyclase inhibitor NO20002967L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19754796A DE19754796A1 (en) 1997-12-10 1997-12-10 Novel azacycloalkane-derived urethanes, their thio and dithio analogues, their salts, pharmaceutical compositions containing them and their use, and processes for their preparation
PCT/EP1998/007965 WO1999029669A1 (en) 1997-12-10 1998-12-08 Urethanes derived from azacycloalkanes, thio and dithio analogues, production and use thereof as 2,3 epoxysqualene lanesterol cyclase inhibitors

Publications (2)

Publication Number Publication Date
NO20002967D0 NO20002967D0 (en) 2000-06-09
NO20002967L true NO20002967L (en) 2000-08-09

Family

ID=7851381

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20002967A NO20002967L (en) 1997-12-10 2000-06-09 Uretans derived from azacycloalkanes, thio and dithio analogues, as well as the use and preparation of 2,3 eposkysqualene-lanesterol cyclase inhibitor

Country Status (27)

Country Link
EP (1) EP1060162B1 (en)
JP (1) JP3418688B2 (en)
KR (1) KR20010032977A (en)
CN (1) CN1281434A (en)
AR (1) AR017827A1 (en)
AT (1) ATE234816T1 (en)
AU (1) AU1759499A (en)
BG (1) BG104500A (en)
BR (1) BR9813495A (en)
CA (1) CA2309388A1 (en)
CO (1) CO5370694A1 (en)
DE (2) DE19754796A1 (en)
DK (1) DK1060162T3 (en)
EA (1) EA200000631A1 (en)
EE (1) EE200000342A (en)
ES (1) ES2190130T3 (en)
HR (1) HRP20000377A2 (en)
HU (1) HUP0100335A3 (en)
IL (1) IL135738A0 (en)
NO (1) NO20002967L (en)
PL (1) PL341060A1 (en)
PT (1) PT1060162E (en)
SK (1) SK8612000A3 (en)
TR (1) TR200001635T2 (en)
WO (1) WO1999029669A1 (en)
YU (1) YU35600A (en)
ZA (1) ZA9811262B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002055497A1 (en) * 2001-01-15 2002-07-18 Glaxo Group Limited Aryl piperidine derivatives as inducers of ldl-receptor expression
EP1351935A1 (en) * 2001-01-15 2003-10-15 Glaxo Group Limited Aryl piperidine derivatives as inducers of ldl-receptor expression
WO2002055496A1 (en) * 2001-01-15 2002-07-18 Glaxo Group Limited Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression
DE10132686A1 (en) * 2001-07-05 2003-01-16 Boehringer Ingelheim Pharma Heteroarylcarboxamides, their preparation and their use as medicines
JP4664634B2 (en) * 2003-09-05 2011-04-06 富山化学工業株式会社 Novel benzamidine derivatives or salts thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04312572A (en) * 1991-04-12 1992-11-04 Takeda Chem Ind Ltd Cyclic amine compound
DE4407138A1 (en) * 1994-03-04 1995-09-07 Thomae Gmbh Dr K New (aminomethyl-benzyl(idene))-aza:cycloalkane carbonyl cpds.
DE4407136A1 (en) * 1994-03-04 1995-09-07 Thomae Gmbh Dr K New amino:methyl substd. aroyl-aza:cycloalkane derivs.

Also Published As

Publication number Publication date
ES2190130T3 (en) 2003-07-16
SK8612000A3 (en) 2000-11-07
AU1759499A (en) 1999-06-28
EE200000342A (en) 2001-08-15
ATE234816T1 (en) 2003-04-15
KR20010032977A (en) 2001-04-25
CO5370694A1 (en) 2004-02-27
HUP0100335A3 (en) 2001-11-28
EA200000631A1 (en) 2000-12-25
DK1060162T3 (en) 2003-07-14
HUP0100335A2 (en) 2001-07-30
DE59807591D1 (en) 2003-04-24
JP3418688B2 (en) 2003-06-23
DE19754796A1 (en) 1999-06-17
PT1060162E (en) 2003-08-29
BR9813495A (en) 2000-10-10
ZA9811262B (en) 2000-06-09
AR017827A1 (en) 2001-10-24
NO20002967D0 (en) 2000-06-09
CA2309388A1 (en) 1999-06-17
IL135738A0 (en) 2001-05-20
YU35600A (en) 2002-09-19
CN1281434A (en) 2001-01-24
WO1999029669A1 (en) 1999-06-17
PL341060A1 (en) 2001-03-26
TR200001635T2 (en) 2000-11-21
BG104500A (en) 2001-03-30
JP2001525397A (en) 2001-12-11
HRP20000377A2 (en) 2000-12-31
EP1060162B1 (en) 2003-03-19
EP1060162A1 (en) 2000-12-20

Similar Documents

Publication Publication Date Title
WO1999033858A3 (en) Estrone sulfamate inhibitors of estrone sulfatase, and associated pharmaceutical compositions and methods of use
TR200100439T2 (en) 1H-Imidazopyridine derivatives
WO2003062259A3 (en) Non-aromatic 17.alpha.-esters of androstane-17.beta.-carboxylate esters as anti-inflammatory agents
CO5570660A2 (en) MODIFIED C-6 INDAZOLILPIRROLOTRIAZINAS
IL135180A0 (en) Sulfonyl derivatives
TW200420542A (en) A compound having TGF β inhibition activity and a medicinal composition containing the same
SE9904652D0 (en) Novel Compounds
YU49443B (en) Benzimidazole derivatives, processes for their preparation, and their use in medical therapy, particulary for treating or preventing viral infections
TW200613297A (en) Pyrazole derivatives
NO980856D0 (en) Piperazine derivatives and process for their preparation
GB2303851A (en) Pharmaceutical diketopiperazine compounds
HUP0100732A2 (en) Synergetic fungicidal composition comprising amide compound and azole derivative and its use
TW200510377A (en) Novel compound having 4-pyridylalkylthio group as substituent
NO20002589L (en) Bifenylamidinderivater
ATE157969T1 (en) DIAMINOTRIFLUOROMETHYLPYRIMIDEINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHOSPHOLIPASE A2 INHIBITORS CONTAINING SAME
NO972887L (en) Piperidinedacetic acid derivatives useful as fibrinogen antagonist agent
NO20002967L (en) Uretans derived from azacycloalkanes, thio and dithio analogues, as well as the use and preparation of 2,3 eposkysqualene-lanesterol cyclase inhibitor
ATE238297T1 (en) QUINOLINE DERIVATIVE
EA200000389A3 (en) New substituted pyridine or piperidine compounds, a process for their preparation and pharmaceutical compositions containing them
ATE75737T1 (en) INDENOTHIAZOLE DERIVATIVES AND PROCESS FOR THEIR PRODUCTION.
NO975402L (en) New Benzopyran Compounds, Methods of Preparing Them and Pharmaceutical Compositions Containing Them
HRP20050617A2 (en) Imidazol derivatives having affinity for alpha 2 receptors activity
MY134226A (en) 1,2-dihydropyrazol-3-ones which control inflammatory cyctokines
BR0013409A (en) Fungicide compounds having a fluorvinyl or fluorpropenyl-oxyphenyloxide portion and process for preparing them
ES2206296T3 (en) DERIVATIVES OF TIENOPIRANOCARBOXAMIDA.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application